CSTONE PHARMA-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Established
- 2018-12-13
- Employees
- 164
- Market Cap
- -
- Website
- http://www.cstonepharma.com
- Introduction
Cornerstone Pharmaceutical was created to meet the needs of cancer patients and focuses on developing and commercializing innovative tumor immunotherapy and molecular-targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team with rich experience in preclinical research, clinical development and commercializa...
A Phase I Study of CS2009 in Participants with Advanced Solid Tumors
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 230
- Registration Number
- NCT06741644
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05700448
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT05381753
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05297890
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
🇨🇳Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳West China Hospital of Sichuan University, Chengdu, China
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 156
- Registration Number
- NCT05279300
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
🇺🇸BUMC - Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
🇦🇺Ashford Cancer Centre Research, Adelaide, South Australia, Australia
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT04421352
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chendu, Sichuan, China
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04338724
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT04254939
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of CS3005 in Advanced Solid Tumors
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT04233060
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Sydney, New South Wales, Australia
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04200404
- Locations
- 🇦🇺
Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia